STX 140

Known as: STX-140, STX140 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2015
01220072015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Despite paclitxael's clinical success, treating hormone-refractory breast cancer remains challenging. Paclitaxel has a poor… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2010
2010
Background:Class III β-tubulin overexpression is a marker of resistance to microtubule disruptors in vitro, in vivo and in the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2009
2009
The anti-proliferative and anti-angiogenic properties of the endogenous oestrogen metabolite, 2-methoxyoestradiol (2-MeOE2), are… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2009
2009
Many anticancer drugs target microtubules and induce apoptosis. However, improved microtubule-targeting drugs, such as STX140 and… (More)
Is this relevant?
2008
2008
PURPOSE The aim of these studies was to characterize the action of STX140 in a P-glycoprotein-overexpressing tumor cell line both… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
Drug combination therapy is a key strategy to improve treatment efficacy and survival of cancer patients. In this study the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
UNLABELLED This study characterises two recently developed anticancer agents in vitro and in vivo, 2-methoxyoestra-1,3,5(10), 16… (More)
Is this relevant?
2008
2008
UNLABELLED There is a continued need for orally bioavailable anticancer compounds that exhibit good efficacy against breast… (More)
Is this relevant?
2008
2008
The steroidal-based drug 2-ethyloestradiol-3,17-O,O-bis-sulphamate (STX243) has been developed as a potent antiangiogenic and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2007
2007
Therapies for hormone-independent prostate and breast cancer are limited, with the effectiveness of the taxanes compromised by… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?